Vol 71, No 4 (2020)
Original paper
Published online: 2020-06-01

open access

Page views 2210
Article views/downloads 2827
Get Citation

Connect on Social Media

Connect on Social Media

Changes in serum thyroid hormone levels in psychiatric patients treated with second-generation antipsychotics

Jia-Xuan Zhang1, Xun Li2
Pubmed: 32901909
Endokrynol Pol 2020;71(4):292-298.

Abstract

Introduction: The objective of the study was to evaluate changes in serum thyroid hormone levels in psychiatric patients after second-generation antipsychotic (SGA) treatment, and to determine differences between monotherapy and  polytherapy with SGAs, as well as differences between patients with and without a history of antipsychotics.

Material and methods: A total of 71 patients with baseline thyroid hormone levels within the normal reference ranges were included in this retrospectively study.

Results: After SGAs treatment, the serum levels of free triiodothyronine (FT3), free thyroxine (FT4), total triiodothyronine (TT3), and total thyroxine (TT4) significantly decreased, and serum thyroid-stimulating hormone (TSH) levels significantly increased (changes from baseline: FT3: –0.31 pmol/L, p < 0.001; FT4: –2.71 pmol/L, p < 0.001; TT3: –0.05 nmol/L, p = 0.024, TT4: –12.36 nmol/L, p < 0.001; TSH: 0.46 mIU/L, p < 0.001). One (1.4%) patient had TSH levels higher than 7 mIU/L. Changes in serum levels of TSH and TT3 between patients with or without a history of antipsychotic drugs were significantly different (changes from baseline: TSH: p < 0.001 vs. p = 0.089; TT3: p = 0.013
vs. p = 0.553). Changes in serum TSH levels had a moderate positive correlation with the average daily dose of SGAs (p = 0.007, r = 0.318).

Conclusions: After SGA treatment, patients seemed to have a trend of hypothyroidism, but the incidence was low. The preliminary results of this study did not show the necessity of regular monitoring of serum thyroid hormone levels in patients with baseline thyroid hormone levels within the normal reference ranges.

Article available in PDF format

View PDF Download PDF file

References

  1. Masana M, Santana N, Artigas F, et al. Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review. Curr Top Med Chem. 2012; 12(21): 2357–2374.
  2. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2020; 25(S2): S12–S21.
  3. Scanlon MF, Weightman DR, Shale DJ, et al. Dopamine is a physiological regulator of thyrotrophin (TSH) secretion in normal man. Clin Endocrinol (Oxf) . 1979; 10(1): 7–15.
  4. Besses GS, Burrow GN, Spaulding SW, et al. Dopamine infusion acutely inhibits the TSH and prolactin response to TRH. J Clin Endocrinol Metab. . 1975; 41(5): 985–988.
  5. Scanlon MF, Mora B, Shale DJ, et al. Evidence for dopaminergic control of thyrotrophin secretion in man. Lancet. 1977; 310(8035): 421–423.
  6. Kelly D, Conley R. Thyroid Function in Treatment-Resistant Schizophrenia Patients Treated With Quetiapine, Risperidone, or Fluphenazine. J Clin Psych. 2005; 66(01): 80–84.
  7. Potkin S, Gharabawi G, Greenspan A, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Res. 2006; 85(1-3): 254–265.
  8. Vedal T, Steen N, Birkeland K, et al. Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication. J Psych Res. 2018; 106: 74–81.
  9. World Health Organization Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/ (Last updated on December 16, 2019.).
  10. Ross DS. Subclinical hypothyroidism in nonpregnant adults. . https://www.uptodate.com/contents/subclinical-hypothyroidismin-nonpregnant-adults (UpToDate. 2019).
  11. Shaw J, Lewis J, Pascal S, et al. A Study of Quetiapine: Efficacy and Tolerability in Psychotic Adolescents. J Child Adolesc Psychopharmacol. 2001; 11(4): 415–424.
  12. Schimmelmann B, Mehler-Wex C, Lambert M, et al. A Prospective 12-Week Study of Quetiapine in Adolescents with Schizophrenia Spectrum Disorders. J Child Adolesc Psychopharmacol. 2007; 17(6): 768–778.
  13. Findling R, Pathak S, Earley W, et al. Efficacy and Safety of Extended-Release Quetiapine Fumarate in Youth with Bipolar Depression: An 8 Week, Double-Blind, Placebo-Controlled Trial. J Child Adolesc Psychopharmacol. 2014; 24(6): 325–335.
  14. Fraguas D, Merchan-Naranjo J, Laita P, et al. Metabolic and Hormonal Side Effects in Children and Adolescents Treated With Second-Generation Antipsychotics. J Clin Psychiatry. 2008; 69(7): 1166–1175.
  15. Ho J, Panagiotopoulos C, McCrindle B, et al. Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry. 2011; 20(3): 234–241.
  16. Li C, Lai J, Huang T, et al. Thyroid functions in patients with bipolar disorder and the impact of quetiapine monotherapy: a retrospective, naturalistic study. Neuropsychiatr Dis Treat. 2019; 15: 2285–2290.
  17. Lambert C, Mazurie A, Lauve N, et al. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord. 2016; 18(3): 247–260.
  18. Hayes J, Marston L, Walters K, et al. Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. PLOS Medicine. 2016; 13(8): e1002058.
  19. Bocchetta A, Cocco F, Velluzzi F, et al. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest. 2014; 30(5): 363–366.
  20. Khalil R, Richa S. Thyroid Adverse Effects of Psychotropic Drugs. Clin Neuropharmacol. 2011; 34(6): 248–255.
  21. Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res. 2013; 6(1): 3.